Compare Agilent Technologies Inc (A) vs Aehr Test Systems (AEHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Aehr Test Systems — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Aehr Test Systems trades at $116.52 (market cap $3.46B). The key difference: Agilent Technologies Inc is far larger — about 12.1× Aehr Test Systems's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| A | AEHR | |
|---|---|---|
Market Cap | $42.00B | $3.46B |
Sector | Health | Technology |
52-Week High | $157.20 | $116.58 |
52-Week Low | $110.24 | $17.38 |
Enterprise Value | $43.55B | $3.36B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
AEHR Test Systems trades at $103.07, up 3.34% with strong technical momentum and bullish moving average signals. The company shows improving earnings trends with three consecutive quarterly beats, though profitability remains negative with a -14.25% net margin. Recent news highlights significant silicon photonics orders and a strategic pivot toward AI infrastructure, driving investor optimism despite insider selling activity.
Outlook remains growth-focused with FY27 revenue guidance of 160-200% expansion, though high valuation (P/S 65.13) and customer concentration pose risks. Analyst consensus leans neutral with 33% buy ratings, while technical indicators suggest near-term support at $97 with resistance at $107. The stock's AI-driven backlog expansion supports bullish sentiment despite current negative cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →
